Amgen Revenue Slipped 1% in the Fourth Quarter

Fourth-quarter revenue for Amgen (NASDAQ: AMGN) slipped 1% year over year to $6.2 billion as the company faced competition from biosimilar and generic competition for its older medications. Adjusted earnings per share increased 6% year over year, boosted by the company's repurchase of 40.2 million shares for $7.6 billion during 2019.